TradingKey

關於 Regenxbio Inc 公司

REGENXBIO Inc. 是一家臨牀階段的生物技術公司，致力於通過基因治療的治癒潛力改善生活。該公司利用其專有的腺相關病毒 (AAV) 基因治療交付平臺 (NAV 技術平臺) 開發了一系列基因治療項目，以治療遺傳疾病。該公司專注於三個領域的內部開發管線：視網膜、神經肌肉和神經退行性疾病。其研究性 AAV 療法包括 ABBV-RGX-314、RGX-202 和 RGX-121。該公司正在與 AbbVie 合作開發 ABBV-RGX-314，以治療受溼性老年性黃斑變性、糖尿病視網膜病變 (DR) 和其他以視力喪失爲特徵的慢性視網膜疾病影響的大量患者羣體。該公司正在開發 RGX-202 來治療杜氏肌營養不良症 (Duchenne)。該公司正在開發 RGX-121 用於治療 II 型粘多糖貯積症 (MPS II)，這是一種進行性神經退行性溶酶體貯積症。

公司簡介

公司代碼RGNX

公司名稱Regenxbio Inc

上市日期Sep 17, 2015

CEOMr. Curran M. Simpson

員工數量353

證券類型Ordinary Share

年結日Sep 17

公司地址9804 Medical Center Drive

城市ROCKVILLE

上市交易所NASDAQ Global Select Consolidated

國家United States of America

郵編20850

電話12405528181

網址https://regenxbio.com/

公司代碼RGNX

上市日期Sep 17, 2015

CEOMr. Curran M. Simpson

公司高階主管

名稱

名稱/職務

職務

持股

持股變動

Mr. Mitchell Chan

Chief Financial Officer, Executive Vice President, Principal Accounting Officer

58.87K

--

Dr. Olivier Danos, Ph.D.

Executive Vice President, Chief Scientific Officer

58.37K

-55.17%

Mr. Curran M. Simpson

President, Chief Executive Officer, Director

31.47K

-13.00%

Ms. Jennifer L. Zachary

Independent Director

20.06K

+63.21%

Mr. Daniel Tasse

Lead Independent Director

19.05K

+68.83%

Mr. George V. Migausky

Independent Director

19.05K

+68.83%

Mr. Craig Malzahn

Executive Vice President - Product Development, Chief Technology Officer

17.82K

--

Mr. Allan M. Fox, J.D.

Director

--

Dr. David C. (Dave) Stump, M.D.

Independent Director

--

Dr. A. N. (Jerry) Karabelas, Ph.D.

Independent Director

--

名稱

名稱/職務

職務

持股

持股變動

Mr. Mitchell Chan

Chief Financial Officer, Executive Vice President, Principal Accounting Officer

58.87K

--

Dr. Olivier Danos, Ph.D.

Executive Vice President, Chief Scientific Officer

58.37K

-55.17%

Mr. Curran M. Simpson

President, Chief Executive Officer, Director

31.47K

-13.00%

Ms. Jennifer L. Zachary

Independent Director

20.06K

+63.21%

Mr. Daniel Tasse

Lead Independent Director

19.05K

+68.83%

Mr. George V. Migausky

Independent Director

19.05K

+68.83%

收入明細

暫無數據

暫無數據

業務

地區

暫無數據

股東統計

更新時間: 5月17日週六

持股股東

股東類型

持股股東

佔比

Redmile Group, LLC

9.52%

BlackRock Institutional Trust Company, N.A.

7.77%

The Vanguard Group, Inc.

6.89%

JP Morgan Asset Management

5.85%

Fox (Allan Mark)

5.76%

Other

64.21%

持股股東

佔比

Redmile Group, LLC

9.52%

BlackRock Institutional Trust Company, N.A.

7.77%

The Vanguard Group, Inc.

6.89%

JP Morgan Asset Management

5.85%

Fox (Allan Mark)

5.76%

Other

64.21%

股東類型

持股股東

佔比

Investment Advisor/Hedge Fund

29.45%

Investment Advisor

29.40%

Hedge Fund

17.30%

Research Firm

8.25%

Individual Investor

7.69%

Sovereign Wealth Fund

2.96%

Pension Fund

0.32%

Bank and Trust

0.25%

Family Office

0.10%

Other

4.27%

機構持股

更新時間: 7月1日週二

報告期間

機構數

持股數

持股佔比

持股變動

2025Q2

421

48.24M

95.74%

-3.52M

2025Q1

446

48.46M

96.35%

-3.90M

2024Q4

444

48.16M

97.22%

-4.82M

2024Q3

444

49.64M

100.43%

-4.45M

2024Q2

437

49.30M

99.98%

-3.20M

2024Q1

451

48.23M

99.21%

+414.63K

2023Q4

436

43.62M

98.84%

-7.14M

2023Q3

439

43.73M

99.56%

-6.26M

2023Q2

439

43.86M

100.57%

-5.31M

2023Q1

456

44.07M

101.46%

-1.49M

股東持股明細

名稱

持股數

佔比

持股變動

變動比例

公告日期

Redmile Group, LLC

4.79M

9.52%

--

Mar 31, 2025

BlackRock Institutional Trust Company, N.A.

3.92M

7.77%

+48.66K

+1.26%

Mar 31, 2025

The Vanguard Group, Inc.

3.47M

6.89%

+495.83K

+16.65%

Mar 31, 2025

JP Morgan Asset Management

2.95M

5.85%

+36.88K

+1.27%

Mar 31, 2025

Fox (Allan Mark)

2.90M

5.76%

+7.77K

+0.27%

May 30, 2025

Morgan Stanley & Co. LLC

1.57M

3.11%

+45.10K

+2.96%

Mar 31, 2025

Balyasny Asset Management LP

1.40M

2.78%

+211.40K

+17.81%

Mar 31, 2025

Dimensional Fund Advisors, L.P.

1.15M

2.28%

-23.70K

-2.02%

Mar 31, 2025

Geode Capital Management, L.L.C.

1.11M

2.2%

+12.72K

+1.16%

Mar 31, 2025

BlackRock Financial Management, Inc.

1.09M

2.17%

-19.59K

-1.76%

Mar 31, 2025

持股ETF

更新時間: 8月2日週六

機構名稱

佔比

WisdomTree BioRevolution Fund

1.81%

iShares Neuroscience and Healthcare ETF

0.92%

Virtus LifeSci Biotech Clinical Trials ETF

0.72%

Global X Genomics & Biotechnology ETF

0.48%

JPMorgan Fundamental Data Science Small Core ETF

0.34%

ALPS Medical Breakthroughs ETF

0.28%

SPDR S&P Biotech ETF

0.13%

iShares Health Innovation Active ETF

0.08%

Direxion Daily S&P Biotech Bull 3X Shares

0.07%

Fidelity Enhanced Small Cap ETF

0.07%

WisdomTree BioRevolution Fund

佔比1.81%

iShares Neuroscience and Healthcare ETF

佔比0.92%

Virtus LifeSci Biotech Clinical Trials ETF

佔比0.72%

Global X Genomics & Biotechnology ETF

佔比0.48%

JPMorgan Fundamental Data Science Small Core ETF

佔比0.34%

ALPS Medical Breakthroughs ETF

佔比0.28%

SPDR S&P Biotech ETF

佔比0.13%

iShares Health Innovation Active ETF

佔比0.08%

Direxion Daily S&P Biotech Bull 3X Shares

佔比0.07%

Fidelity Enhanced Small Cap ETF

佔比0.07%

分紅派息

近5年累計派現 0.00 美元

公告日期

分紅計劃

股權登記日

現金發放日

除權除息日

暫無數據

拆合股

公告日期

類型

比率

暫無數據

公告日期

類型

比率

暫無數據

Regenxbio Inc

8.290USD

Regenxbio Inc

8.290

概覽

公司

財務